双重载药多层海藻酸盐-壳聚糖缓释微球的制备及体外释放

采用滴注法将海藻酸钠与钙离子交联,制成负载血管内皮生长因子(VEGF)的藻酸钙核心球,利用层层自组装技术在核心球的表面依次包覆壳聚糖、海藻酸和壳聚糖,壳聚糖中负载万古霉素(VAN),形成多药载药缓控体系.采用正交实验考察海藻酸钠浓度、钙离子浓度及壳聚糖浓度对VEGF和VAN的药物包封率和载药量的影响,优化了制备工艺.采用扫描电子显微镜观察多层微球的表面、截面形貌及粒径,采用傅里叶变换红外光谱检测海藻酸盐与壳聚糖的自组装情况,分别采用酶联免疫吸附(ELISA)双抗体夹心法和紫外分光光度法检测VEGF和VAN的包封率、载药量及体外释放情况.结果表明,海藻酸钠最优浓度为0.04g/mL,氯化钙最优浓度为0.15g/mL,壳聚糖最优浓度为0.01g/mL.微球光滑圆整,均质实心,直径900~1100μm,VEGF的包封率达61.31%,VAN的包封率为3.48%.体外释放实验结果表明,VEGF缓释时间为15.5d,并出现2个释放高峰;VAN缓释时间为4.5d,释药情况平稳持续,无明显突释.双重载药多层包覆微球兼具控制感染和促进血管生成两种潜能,有望应用于组织工程骨的基础研究和临床实践.     

微乳液成核-离子交联制备阿司匹林/壳聚糖纳米微球及其体外释放行为

以自制阿司匹林为药物模型,壳聚糖(CS)为载体源,采用微乳液成核-离子交联法制备了阿司匹林/壳聚糖纳米缓释微球.分别用傅里叶变换红外(FTIR)光谱、场发射扫描电子显微镜(FESEM)、透射电子显微镜(TEM)、动态激光光散射(DLLS)、X射线粉末衍射(XRD)等表征了纳米微粒的化学组成、外观形貌、平均粒径和粒径分布、微球中壳聚糖的晶体结构以及阿司匹林的分布形态.结果表明,利用微乳液成核-离子交联法制备的阿司匹林/壳聚糖微球平均粒径约为88nm且粒径分布均匀,成核后壳聚糖结晶形态基本未变,阿司匹林以分子形态分布于微粒中,分子间未形成堆砌,为无定形态.采用UV-Vis分光光度计考察了微球的药物包封率、载药量,并对微球在生理盐水和葡萄糖溶液中的释药行为进行跟踪.结果表明,微球的载药量可达55%,药物包封率可达42%,实验条件下具有较好的药物缓释作用.     

淫羊藿苷壳聚糖/明胶微球的制备及其体外释放研究

本试验以壳聚糖、明胶为载药基质,以中药淫羊藿苷为模拟药物,通过乳化交联的方法制备淫羊藿苷/壳聚糖/明胶微球。考察微球的理化特性,建立持续流动释放系统,检测了微球的体外释放特性和影响因素。微球的理化特性受工艺条件如搅拌速度、乳化剂用量、交联剂用量等因素影响。微球的体外释放速率与微球的粒径、交联度负相关,与载药量正相关。试验结果表明,壳聚糖、明胶可作为缓释微球的载体基质,微球制备工艺简单稳定,微球的释放速率可控,淫羊藿苷/壳聚糖/明胶微球是一种良好的药物释放体系。     

生物降解聚酯包埋利福平缓释微球的制备及释放行为

以生物可降解乙交酯和丙交酯的无规共聚物(PLGA)为载体,将抗结核病药利福平溶解于PLGA的有机溶液中,采用通常乳化-溶剂挥发方法制备了药物缓释微球.研究了影响微球制备的工艺条件.用电子显微镜观察了微球及降解后的表面形态,测定了微球粒径及载药量,评价了载药微球的体外释放行为.结果表明,以质量分数为1%的明胶为稳定剂,制备的微球形态完整,粒径范围为10～30μm,微球中利福平的平均质量分数为24.3%.体外释药时间可以通过高分子的降解速率来调控,本实验的释药时间可以在42～84d之间调控,药物缓释达到了理想的零级动力学释放.因此,利福平PLGA微球具有显著的长效、恒量药物缓释作用.     

生物降解多功能缓释微球的制备与表征

通过羧甲基壳聚糖接枝二甲基十八烷基环氧丙基氯化铵, 合成水油两溶性的羧甲基壳聚糖十八烷基季铵盐(OQCMC); 并将其作为乳化剂与乳酸-羟基乙酸(PLGA)和羟乙基纤维素(HEC)复合, 利用溶剂挥发法, 构建一种多功能的药物载体缓释系统, 并尝试包裹脂溶性药物盐酸米诺环素. 利用Transmission electron microscopy, Quasielastic laser light scattering, Zeta电位仪, FTIR, 1H NMR等对OQCMC及载药微球进行表征, 并进行药物的体外释放实验. 结果表明: OQCMC可作为一种优良的乳化剂对PLGA微球进行修饰; 并可使复合微球体系带正电, 在提高微球载药率(9.4%)的同时减小微球粒径[(166.4±0.8) nm]; 复合微球体系对盐酸米诺环素具有较好的物理包裹能力, 并有长效缓释作用(PBS, pH＝7.9).     

香草醛交联壳聚糖载药微球的性能及其成球机理分析

以壳聚糖溶液为水相、液体石蜡为油相形成油包水型乳液, 以香草醛为交联剂, 采用乳化交联法制得壳聚糖微球. 结合IR光谱和XRD测试, 分析了壳聚糖交联固化成球的机理: 壳聚糖和香草醛之间所发生的Schiff碱反应和氢键的形成以及缩醛化反应, 以此为基础共同形成交联结构从而使壳聚糖交联固化成球. 探讨了交联后壳聚糖微球结晶度降低的原因: 壳聚糖固化时分子链未充分进行有序的结晶排列, 交联后的壳聚糖结构较复杂, 从而破坏了原壳聚糖分子的规整性. 选用盐酸小檗碱为模型药物, 制备了香草醛交联的壳聚糖载药微球, SEM结果显示, 载药微球表面致密且球形度好, 微球粒径在5-15 μm之间. 此外, 采用分光光度计对载药微球的载药率、药物包封率和药物体外释放性质进行了测试和分析, 结果表明载药微球缓释效果明显.     

壳交联pH响应型PLGA载药微球的制备与研究

首先采用一次乳化法制备出PLGA[聚(乳酸-羟基乙酸)]纳米微球,并通过静电吸附将阳离子聚合物壳聚糖修饰到PLGA微球表面,然后以香草醛为交联剂对壳聚糖进行化学交联,得到一种壳交联的p H响应型纳米微球(PCV),微球粒径为(277.60±38.01)nm,表面电位为(21.60±4.51)m V.微球稳定性评价结果显示微球在24 h内粒径变化较小;流式细胞仪检测显示细胞对PCV微球的摄取量比未经修饰的PLGA微球的摄取量高;空白微球细胞毒性实验表明在空白微球浓度小于80μg/m L时细胞的存活率达93.24%.以多西他赛(DTX)为模型药物进行包载,该纳米微球DTX的载药率为7.48%,包封率为34.98%;体外药物释放实验显示,该微球在p H=5.0环境下孵育90 h的药物积累释放率达58.66%,而在p H=7.4的环境下的药物积累释放率为50.63%;此外,载DTX微球毒性试验结果表明该载药微球对A549肺癌细胞有较强的杀伤作用,其IC50值可达0.0009μg/m L.     

层层自组装芸香叶苷海藻酸钠/壳聚糖盐酸盐微球的制备及释药性研究

为了提高载药微球的成球性和机械性能,以搅拌共沉淀法制得的CaCO_3微球为吸附剂,采用离子交联法制备载芸香叶苷的海藻酸钙(ALG-Ca)模板凝胶,利用层层自组装技术(LBL)将带有相反电荷的海藻酸钠(ALG)和壳聚糖盐酸盐(CHI)逐层络合得到不同膜层的载芸香叶苷微球。通过FT-IR、SEM、溶胀实验和体外释药实验对载药微球的性能进行研究,结果表明,以CaCO_3微球为吸附剂可提高载药ALG-Ca/(CHI/ALG)3微球的机械性能和成球性,微球剖面边缘出现层层膜结构且膜层总厚度约为20.22μm,载芸香叶苷ALG-Ca/(CHI/ALG)n微球释药实验发现,在37℃、pH=1.2生理盐水和pH=6.8 PBS溶液的环境下,聚合物膜层数越多对芸香叶苷缓释能力越强。     

左旋多巴-壳聚糖微球的制备及其释药性能

采用乳化分散-离子交联法,以三聚磷酸钠为离子交联剂,制备了左旋多巴-壳聚糖微球,并考察其理化性质和药物释放性能。偏光显微镜观察表明,得到的微粒基本成球;经激光粒度仪测定,其平均粒径约为3.5μm。红外光谱分析表明,壳聚糖中的氨基质子化后与三聚磷酸钠以静电结合,而左旋多巴则被包裹在壳聚糖微球内。DSC及XRD分析结果表明,微球内部存在左旋多巴结晶,而壳聚糖则以无定形聚集态存在。TG分析结果表明,壳聚糖与三聚磷酸钠结合后分解温度降低。微球的药物释放性能显pH依赖性,在酸性环境下,微球的释药速率随壳聚糖浓度的增加而降低,随载药比例的增大而降低;而在碱性介质中总体的释药速率要比酸性介质中的大。     

酮洛芬/酸改性蒙脱土缓释体系的制备及体外释药研究

以盐酸改性蒙脱土为药物载体,采用离子交换法制备了酮洛芬/酸改性蒙脱土(KPF/acid-MMT)复合物.借助X射线衍射(XRD)、比表面积分析和扫描电子显微镜(SEM)等手段对复合物进行了结构表征;采用透析法研究了介质pH值对KPF/acid-MMT释放性能的影响;运用3种数学模型对其体外释放行为进行拟合.结果表明:经酸改性后,蒙脱土的比表面积由19.66 m~2/g增加到202.84 m~2/g,载药量由18.09%提高到37.24%;在人工模拟胃液(pH=1.2)和人工模拟肠液(pH=6.8)中,酮洛芬的累积释放量分别为18.6%和86.7%;零级动力学模型能更好地拟合和描述KPF/acid-MMT在人工模拟肠液中的体外释放行为.酸改性蒙脱土能有效提高药物的负载量,KPF/acid-MMT可实现药物的定向释放和缓释性能,有望制成肠道缓释口服药物制剂.     

Simple coacervates of zein to encapsulate Gitoxin

This work reports the use of simple coacervates of the hydrophobic protein zein to encapsulate Gitoxin, a cardiotonic glycoside. The microspheres obtained using ethanol, methanol, iso-propyl alcohol were characterized using viscosity index, scanning electron microscopy (SEM) and laser light scattering particle analyzer. Scanning electron micrographs indicated that the zein film was made of microspheres with diameter in the 1-1.5 microm range, which could be controlled. Sizes of Gitoxin-loaded zein microspheres changed little before and after release of the drug because of conglutination among zein microspheres. Release of Gitoxin from zein microspheres, were performed in vitro to investigate the mechanism of model drug release. The results show that the zein microspheres obtained using ethanol are best suited for use as a sustained-release form of Gitoxin. The microspheres may also be useful in drug targeting system since the diameter of the microspheres is appropriate for phagocytosis by macrophages. Both zein film and Gitoxin-loaded zein microsphere film were effective in suppressing platelet adhesion.     

Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion-solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oil

The purpose of this study was to design a sustained-release formulation of an oily drug. The sustained-release microspheres with self-emulsifying capability containing zedoary turmeric oil (ZTO) were prepared by the quasi-emulsion-solvent-diffusion method. The micromeritic properties, the efficiency of emulsification and the drug-release behavior of the resultant microspheres were investigated. The bioavailability of the microspheres was compared with conventional ZTO self-emulsifying formulations for oral administration using 12 healthy rabbits. An HPLC method was employed to determine the concentration of germacrone in plasma, which was used as an index of ZTO. Spherical and compacted microspheres with average diameters of 100-600 microm have been prepared, and their release behavior in distilled water containing 1.2% (w/v) of polysorbate-80 can be controlled by the ratio of polymer/Areosil200 in the microspheres. The resultant emulsions with mean droplet sizes of 200-500 nm are produced when the microspheres are immersed in phosphate buffer (pH 6.8) under gentle agitation. The stability and the droplet size of the resultant emulsions are also affected by the polymer/Areosil200 ratio in the formulation, while the amount of talc has a marked effect on the self-emulsifying rate. The plasma concentration-time profiles with improved sustained-release characteristics were achieved after oral administration of the microspheres with a bioavailability of 135.6% with respect to the conventional self-emulsifying formulation (a good strategy for improving the bioavailability of an oily drug). In conclusion, the sustained-release microspheres with self-emulsifying capability containing ZTO have an improved oral bioavailability. Our study offers an alternative method for designing sustained-release preparations of oily drugs.     

Synthesis and application of a dual functional P/N/S‐containing microsphere with enhanced flame retardancy and mechanical strength on EP resin

A phosphazene derivative flame retardant with a highly cross‐linked microsphere structure, named poly(cyclotriphosphazene‐c‐sulfonyldiphenol) (PCPS) microspheres, were synthesized by 1‐pot reaction and then applied on flame retarded epoxy (EP) resin. The microstructure and chemical composition of PCPS microspheres were characterized using scanning electron microscopy, transmission electron microscopy, and element mapping. The thermal stability of PCPS microspheres and PCPS/EP composites was explored through thermogravimetric analysis. Thermogravimetric data showed that the PCPS microspheres have excellent thermal stability, and the char yield is about 43% at the end of 800°C. The incorporation of PCPS microspheres significantly increased the char yield of PCPS/EP composites. The flammability was investigated by limited oxygen index tests and cone calorimeter. The limited oxygen index value of PCPS/EP composite was increased to 29.8 from 26.6 when 3 wt% of PCPS microspheres was added. Compared with neat EP, the flame retardancy was greatly improved. The peak heat release rate and smoke production rate of PCPS/EP composites were reduced by 45.0% and 43.6%, respectively. The mechanical properties including tensile strength and modulus were both improved due to the enhancement of PCPS microspheres. The PCPS microspheres act as a dual function for improving both the flame resistance and mechanical strength of PCPS/EP system.     

海藻酸壳聚糖可塑性支架材料的制备及表征

利用海藻酸钠和壳聚糖2种原料, 采用阴阳离子静电复合原理, 通过滴注法层层自组装成可搭载药物的缓释微球, 再按一定比例与海藻酸钠-壳聚糖溶液混合制成缓释微球型支架材料, 将缓释微球结构嵌入疏松多孔海绵状结构中. 研究了缓释微球的组分比对缓释微球型支架材料的孔隙率、 收缩率、 亲水性及降解性能的影响; 扫描电子显微镜照片显示, 微球结构相对完整, 多孔海绵状结构孔径为140~200 μm; 支架浸出液细胞毒性检测实验组对照组未见差异. 缓释微球体积所占比例即组分比为10%的缓释微球型支架材料孔隙率最高为68.2%~70.8%, 亲水性最好, 收缩率最低为4.4%~5.2%; 支架降解速率随缓释微球组分比升高而减慢, 组分比为20%的缓释微球型支架材料综合性能更优; 缓释微球型支架材料冻干成型前为液态, 具有良好可塑性. 缓释微球型支架材料为缓释系统与多孔支架材料有机结合提供了新思路.     

聚[碳酸(亚丁酯-co-ε-己内酯)酯]的制备及其载药微球性能的研究

采用阴离子配位聚合方法, 合成了二氧化碳、1,2-环氧丁烷与ε-己内酯的三元共聚物: 聚[碳酸(亚丁酯-co-ε-己内酯)酯](PBCL). 并采用复相乳液(W/O/W)溶剂挥发法制备了包裹抗菌药物甲磺酸帕珠沙星的可降解微球. 对聚合物进行了FTIR, ¹H NMR, ¹³C NMR, DSC, TGA和WAXD等表征, 以及降解性能和载药微球特性的研究. 结果表明, PBCL热稳定性及降解性能优于聚碳酸亚丁酯(PBC). 所得PBCL微球球形规整、表面光滑. 大部分微球粒径在0.5～1 μm的范围内, 载药量和包封率分别达到38.21%和87.9%. 微球的体外释药性能研究在pH 7.4的磷酸缓冲溶液中进行, 释放21 d后, PBCL微球的累积释药量为84.74%, PBC微球的释药量仅为17.29%. 药物的体外释放行为符合Higuchi方程. PBCL载药微球具有长效缓释作用.     

Formulation and evaluation of quince seeds mucilage – sodium alginate microspheres for sustained delivery of cefixime and its toxicological studies

Quince seed mucilage was used in a combination of sodium alginate to develop sustained-release microspheres of cefixime. Physical characterizations such as FTIR, TGA, DSC, and SEM were performed on the prepared microspheres. The swelling of microspheres was maximum at pH 7.4 and reduced at acidic pH. The average particle size ranged from 679 µm ± 0.21 to 810 µm ± 0.31, while the drug encapsulation efficiency range was found as 73.76 ± 0.24–85.63 ± 0.46. In vitro release profile of QSM-alginate-cefixime microspheres followed Korsmeyer-Peppas model (R² = 0.9732-–0.9946); and release was non-Fickian as we found value of n > 1. This study reveals the benefits of QSM-alginate microspheres for the sustained release of cefixime without any toxicity and it also improved antibacterial properties.     

Synthesis of bio‐based poly (cyclotriphosphazene‐resveratrol) microspheres acting as both flame retardant and reinforcing agent to epoxy resin

A highly cross‐linked poly (cyclotriphosphazene‐resveratrol) microsphere (PRV) was synthesized by using hexachlorocyclotriphosphazene (HCCP) and bio‐based resveratrol (REV) as raw materials, and the obtained PRV microspheres were applied to improve the flame retardancy and mechanical property of epoxy resin (EP). The TGA results showed that the PRV microsphere is an excellent charring agent and the char yield is as high as 62% at 800°C. The incorporation of PRV makes the initial degradation earlier yet significantly increases the char residue of EP composites. Moreover, the introduction of PRV microspheres into EP greatly promoted the flame retardancy performance. Under 3% of addition of PRV microspheres, the peak heat release rate (PHRR) and total heat release (THR) were decreased by 58.3% and 29.6%, respectively, the limited oxygen index (LOI) value was increased to 29.7% from 25.3% of pure EP. In addition, because of the uniform distribution in EP matrix and the enhancing effect of PRV microspheres, the mechanical properties including tensile modulus of EP composites were strengthened. PRV microspheres in this paper provide a possibility to synthesize a dual functional filler, which acts as both flame retardant and strengthening agent.     

Integration of Mesoporous Bioactive Glass Nanoparticles and Curcumin into PHBV Microspheres as Biocompatible Composite for Drug Delivery Applications

Bioactive glasses (BGs) are being increasingly considered for biomedical applications. One convenient approach to utilize BGs in tissue engineering and drug delivery involves their combination with organic biomaterials in order to form composites with enhanced biocompatibility and biodegradability. In this work, mesoporous bioactive glass nanoparticles (MBGN) have been merged with polyhydroxyalkanoate microspheres with the purpose to develop drug carriers. The composite carriers (microspheres) were loaded with curcumin as a model drug. The toxicity and delivery rate of composite microspheres were tested in vitro, reaching a curcumin loading efficiency of over 90% and an improving of biocompatibility of different concentrations of MBGN due to its administrations through the composite. The composite microspheres were tested in terms of controlled release, biocompatibility and bioactivity. Our results demonstrate that the composite microspheres can be potentially used in biomedicine due to their dual effects: bioactivity (due to the presence of MBGN) and curcumin release capability.     

In vitro degradation and release behavior of porous poly(lactic acid) scaffolds containing chitosan microspheres as a carrier for BMP-2-derived synthetic peptide

To develop a novel tissue engineering scaffold with the capability of controlled releasing BMP-2-derived synthetic peptide, porous poly(lactic acid)/chitosan microspheres (PLA/CMs) composites containing different quantities of chitosan microspheres were prepared by a thermally induced phase separation method. FTIR analysis revealed that there were strong hydrogen bond interactions between the PLA and chitosan component. Introduction of less than 30% CMs (on PLA weight basis) did not remarkably affect the morphology and porosity of the PLA/CMs scaffolds. The compressive strength of the composite scaffolds increased from 0.48 to 0.66 MPa, while the compressive modulus increased from 7.29 to 8.23 MPa as the microspheres' contents increased from 0% to 50%. In vitro degradability investigation indicated that the dissolution of chitosan component was preferential than PLA matrix and the inclusion of CMs could neutralize the acidity of PLA degradation products. Compared with the rapid release from CMs, the synthetic peptide was released from PLA/CMs scaffolds in a temporally controlled manner, mainly depending on the degradation of PLA matrix. The promising microspheres based scaffold release system can be used to deliver bioactive factors for a variety of non-loaded bone regeneration and tissue engineering application.     

高分子载体材料在药用微球中的应用及进展

微球给药系统可实现药物的靶向给药,其在药物的缓控释放等方面表现出良好的应用前景,因而成为近年来药剂学领域的研究热点之一。高分子载体材料（Polymer Carriers）是随着药物学研究、生物材料科学和临床医学的发展而新兴起来的,是一类具有优良生物相容性、生物可降解性、可加工性,经过安全性评价并应用于药物制剂的高分子辅...